Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / SBBP - Checking In On Corcept Therapeutics

SBBP - Checking In On Corcept Therapeutics

Strongbridge Biopharma plc
  • Corcept Therapeutics Incorporated is working to improve on Korlym, its cortisol regulator and sole source of its $350 million plus top line, with next-generation relacorilant.
  • In addition to Cushing’s Syndrome, relacorilant has demonstrated statistically significant efficacy in combination with chemotherapy in the treatment of ovarian cancer, prompting a pivotal trial.
  • With exogenous threats to Korlym, multiple shots on goals from other cortisol regulator candidates, and insider buying, Corcept merited a deeper dive.
  • A full investment analysis follows in the paragraphs below.

For further details see:

Checking In On Corcept Therapeutics
Stock Information
Company Name: Strongbridge Biopharma plc
Stock Symbol: SBBP
Market: NASDAQ
Website: strongbridgebio.com
Menu
SBBP SBBP Quote SBBP Short SBBP News SBBP Articles SBBP Message Board
Get SBBP Alerts

News, Short Squeeze, Breakout and More Instantly...